Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile (C. diff) infection.
C. diff Prevention
Age Range:
65
Gender:
Male and Female
Location:
Rochester, New York
About the Study
C. difficile (C. diff) is a bacterium that can cause infection of the large intestine, leading to symptoms ranging from diarrhea to severe, life-threatening complications. These infections are more common in older adults, especially those who have recently used antibiotics or had hospital stays.
Researchers are working to develop vaccines that may help prevent C. diff infections before they occur. This study is evaluating an investigational vaccine to better understand its safety, tolerability, and how well it may help protect against C. diff infection.
Participants in this study will receive either the investigational C. diff vaccine or a placebo (an inactive substance that looks like the vaccine but does not contain active ingredients). There is a 50% chance of receiving placebo.
Participation in the study will last approximately 3.5 years and includes scheduled clinic visits, telephone check-ins, and regular follow-up.
Qualifications
You may be able to join if you:
- Are 65 years of age or older.
- Do not have a history of C. diff infection.
- Have at least one risk factor for C. diff infection, such as recent hospitalization, frequent healthcare visits, or recent antibiotic use.
- Are not currently experiencing frequent diarrhea or active gastrointestinal conditions.
- Do not have certain medical conditions that may affect participation, such as severe immunodeficiency or unstable health conditions.
- At least 1 inpatient hospitalization for >2 nights duration in the past year, or at least 2 emergency room visits in the past year
FEATURED STUDIES
Researchers are studying an investigational medication to see how effective it may be as a potential weight reduction treatment. If […]
Adults 18 years and older may qualify for a study evaluating investigational treatment options for diabetic peripheral neuropathic pain (DPNP), […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study […]